Crescent Biopharma
CBIO
58 hedge funds and large institutions have $416M invested in Crescent Biopharma in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 16 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 15
23% more capital invested
Capital invested by funds: $338M → $416M (+$78M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.07% less ownership
Funds ownership: 0.98% → 0.91% (-0.07%)
16% less funds holding
Funds holding: 69 → 58 (-11)
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $195K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$7.21M |
| 2 |
NC
Nexthera Capital
New York
|
+$3.77M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$3.05M |
| 4 |
Renaissance Technologies
New York
|
+$2.76M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.12M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.58M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.26M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.1M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.51M |
CBIO Hedge Fund Activity: Q3 2017 in Review
58 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2017, worth a combined $416M — up 23% from $338M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CBIO and 6 opened new positions — a net loss of 10 holders — while 15 trimmed existing stakes and 25 added.
The largest buyer was Redmile Group, adding an estimated $7.21M. The largest seller was Millennium Management, cutting an estimated $8.12M.
- 58 institutional investors held Crescent Biopharma (CBIO) as of Q3 2017, down from 69 in Q2 2017.
- Funds reported $416M of Crescent Biopharma stock for Q3 2017, up 23% quarter-over-quarter.
- 6 funds opened new Crescent Biopharma positions in Q3 2017 and 16 closed out, a net change of -10 holders.
- The largest Crescent Biopharma buyer in Q3 2017 was Redmile Group, an estimated $7.21M added.
- The largest Crescent Biopharma seller in Q3 2017 was Millennium Management, an estimated $8.12M sold.
Based on aggregated 13F filings for Q3 2017.